Cargando…

An Overview of Cefiderocol’s Therapeutic Potential and Underlying Resistance Mechanisms

Antimicrobial resistance continues to increase globally and treatment of difficult-to-treat (DTT) infections, mostly associated with carbapenem-resistant (CR) Pseudomonas aeruginosa, CR Acinetobacter baumannii, and CR- and third-generation-cephalosporins-resistant Enterobacterales remains a challeng...

Descripción completa

Detalles Bibliográficos
Autores principales:	Domingues, Sara, Lima, Tiago, Saavedra, Maria José, Da Silva, Gabriela Jorge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382032/ https://www.ncbi.nlm.nih.gov/pubmed/37511802 http://dx.doi.org/10.3390/life13071427

Ejemplares similares

Cefiderocol: An Overview of Its in-vitro and in-vivo Activity and Underlying Resistant Mechanisms
por: Yao, Jiahui, et al.
Publicado: (2021)

Manure as a Potential Hotspot for Antibiotic Resistance Dissemination by Horizontal Gene Transfer Events
por: Lima, Tiago, et al.
Publicado: (2020)

Plasmid-Mediated Colistin Resistance in Salmonella enterica: A Review
por: Lima, Tiago, et al.
Publicado: (2019)

Cefiderocol, a new antibiotic against multidrug-resistant Gram-negative bacteria
por: Silva, José Tiago, et al.
Publicado: (2021)

Exploring Cefiderocol Resistance Mechanisms in Burkholderia pseudomallei
por: Hall, Carina M., et al.
Publicado: (2023)

Mechanism of action of cefiderocol
por: Soriano, Alex, et al.
Publicado: (2022)

Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance
por: Karakonstantis, Stamatis, et al.
Publicado: (2022)

Cefiderocol
por: Soriano, María Cruz, et al.
Publicado: (2022)

1455. Potential Mechanisms of Cefiderocol MIC Increase in Enterobacterales in In Vitro Resistance Acquisition Studies
por: Yamano, Yoshinori, et al.
Publicado: (2020)

In Vitro Activity of Cefiderocol on Multiresistant Bacterial Strains and Genomic Analysis of Two Cefiderocol Resistant Strains
por: Padovani, Michela, et al.
Publicado: (2023)

Cefiderocol. Summary and conclusions
por: Mensa, José, et al.
Publicado: (2022)

Clinical experience of cefiderocol
por: Fariñas, María Carmen
Publicado: (2022)

Evolution of β-lactamase-mediated cefiderocol resistance
por: Fröhlich, Christopher, et al.
Publicado: (2022)

Occurrence and Biological Cost of mcr-1-Carrying Plasmids Co-harbouring Beta-Lactamase Resistance Genes in Zoonotic Pathogens from Intensive Animal Production
por: Lima, Tiago, et al.
Publicado: (2022)

Interplay between Colistin Resistance, Virulence and Fitness in Acinetobacter baumannii
por: Da Silva, Gabriela Jorge, et al.
Publicado: (2017)

An Overview on Conventional and Non-Conventional Therapeutic Approaches for the Treatment of Candidiasis and Underlying Resistance Mechanisms in Clinical Strains
por: Salazar, Sara B., et al.
Publicado: (2020)

Co-regulation of biofilm formation and antimicrobial resistance in Acinetobacter baumannii: from mechanisms to therapeutic strategies
por: Mendes, Sérgio G., et al.
Publicado: (2023)

Antibacterial spectrum of cefiderocol
por: Cordero, Desirée Gijón, et al.
Publicado: (2022)

Progressive in vivo development of resistance to cefiderocol in Pseudomonas aeruginosa
por: Sadek, Mustafa, et al.
Publicado: (2022)

Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms
por: Sajib, Monirul I., et al.
Publicado: (2023)

Rapid detection of cefiderocol susceptibility/resistance in Acinetobacter baumannii
por: Raro, Otávio Hallal Ferreira, et al.
Publicado: (2023)

Disc Diffusion and ComASP(®) Cefiderocol Microdilution Panel to Overcome the Challenge of Cefiderocol Susceptibility Testing in Clinical Laboratory Routine
por: Bianco, Gabriele, et al.
Publicado: (2023)

Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia
por: Katsube, Takayuki, et al.
Publicado: (2021)

Proteomic Investigation of the Antibacterial Mechanism of Cefiderocol against Escherichia coli
por: Du, Gao-Fei, et al.
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol
por: Bilal, Muhammad, et al.
Publicado: (2021)

The role of cefiderocol in clinical practice
por: Maseda, Emilio, et al.
Publicado: (2022)

Pharmacokinetics/Pharmacodynamics and tolerability of cefiderocol in the clinical setting
por: Perea, José Ramón Azanza, et al.
Publicado: (2022)

Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance
por: Simner, Patricia J, et al.
Publicado: (2021)

Validation and Application of an HPLC-UV Method for Routine Therapeutic Drug Monitoring of Cefiderocol
por: Zimmer, Julia, et al.
Publicado: (2021)

Erratum to: Education: The role of the first siderophore cephalosporin Fetcroja(®) (cefiderocol) in UK clinical practice: introduction; Education: An introduction to the core data for cefiderocol with reflections for a possible role within UK clinical practice; Education: A compassionate use of cefiderocol to treat osteomyelitis caused by an XDR Pseudomonas aeruginosa; Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infection; Education: An overview from the author of ‘Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients’
Publicado: (2021)

Erratum to: Education: The role of the first siderophore cephalosporin Fetcroja(®) (cefiderocol) in UK clinical practice: introduction; Antibiotic resistance during and beyond COVID-19; Education: An introduction to the core data for cefiderocol with reflections for a possible role within UK clinical practice; Education: A compassionate use of cefiderocol to treat osteomyelitis caused by an XDR Pseudomonas aeruginosa; Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infection; Education: An overview from the author of ‘Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients’
Publicado: (2021)

Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations
por: Marino, Andrea, et al.
Publicado: (2022)

Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens
por: Bonomo, Robert A
Publicado: (2019)

Combating antimicrobial resistance with cefiderocol for complicated infections involving the urinary tract
por: Wang, Hongmei, et al.
Publicado: (2022)

Cefiderocol Retains Antibiofilm Activity in Multidrug-Resistant Gram-Negative Pathogens
por: Pybus, Christine A., et al.
Publicado: (2021)

Erratum to: Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia
por: Katsube, Takayuki, et al.
Publicado: (2021)

Cefiderocol for Carbapenem-Resistant Bacteria: Handle with Care! A Review of the Real-World Evidence
por: Sansone, Pasquale, et al.
Publicado: (2022)

2752. Outcomes of Patients with Stenotrophomonas maltophilia infections treated with Cefiderocol in PROVE (Retrospective Cefiderocol Chart Review) Study
por: Marcella, Stephen, et al.
Publicado: (2023)

Multidrug-resistant Serratia rubidaea strains in the oral microbiota of healthy horses
por: da Costa Pimenta, José, et al.
Publicado: (2021)

Education: An overview from the author of ‘Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients’
por: Falcone, Marco
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uhejrh2sssdmv2uq6u5qh4deo0